By VETTAPHARMA reporter: Insmed Incorporated (Nasdaq: INSM) in it fourth-quarter and full-year financial results for 2025, reported total revenues of $606.4 million for the year, supported by continued growth of its commercial products BRINSUPRI® and ARIKAYCE®. Alongside financial results, the company provided a business update outlining 2026 revenue expectations and pipeline advancement priorities.
For the full year ended December 31, 2025, ARIKAYCE total revenues reached $433.8 million, marking 19% year-over-year growth and exceeding the upper end of its prior guidance range. BRINSUPRI total revenues were $172.7 million, including $144.6 million in the fourth quarter, reflecting continued uptake following its commercial launch. Insmed ended the year with approximately $1.4 billion in cash, cash equivalents, and marketable securities.
Despite strong top-line growth, Insmed reported elevated expenses, with a net loss of $328.5 million in Q4 2025 and a full-year net loss of $1.28 billion, underscoring ongoing investment in commercial expansion and research programs. Cost of product revenues, R&D, and selling, general and administrative expenses all increased during 2025 compared with 2024.
2026 Guidance and Strategic Priorities
Looking ahead, Insmed anticipates full-year 2026 revenues for BRINSUPRI of at least $1 billion and expects ARIKAYCE revenues between $450 million and $470 million, implying company-wide revenue growth in 2026 versus 2025. The company also plans to support multiple clinical and regulatory milestones, including Phase 3 ENCORE topline readouts for ARIKAYCE and Phase 3 expansion studies for treprostinil palmitil inhalation powder (TPIP).
Product development updates include ongoing advancement of TPIP trials across pulmonary hypertension and related indications, continued enrollment in key clinical studies, and expansion of earlier-stage assets such as INS1148 and others targeting inflammatory and rare disease indications. Regulatory efforts include planned submissions and label expansions in the U.S., EU, and Japan for key products.
Operational and Pipeline Highlights
Insmed’s 2025 progress reflects substantial commercial momentum for BRINSUPRI and ARIKAYCE, with strong year-over-year revenue growth and continued geographic expansion. Research and development efforts remain robust, with multiple trials ongoing and additional potential regulatory milestones anticipated in 2026 that may further expand the company’s therapeutic reach.
Source credit:
- Insmed Incorporated. (2026, February 19). Insmed reports fourth-quarter and full-year 2025 financial results and provides business update. Click here
